---

Human Papillomavirus (HPV) and Its Role in the Pathogenesis of Cervical Carcinoma

---

1. HPV: The Virus

Virology and Classification

---

HPV Risk Classification

Key Fact: HPV-16 and HPV-18 together account for approximately 70% of all cervical cancers worldwide. HPV-16 predominates in squamous cell carcinoma; HPV-18 has a greater propensity for adenocarcinoma of the endocervix.

• Berek & Novak's Gynecology, p. 842; Henry's Clinical Diagnosis, p. 1844

---

2. The Anatomical Target: Transformation Zone

• At menarche, estrogen stimulates lactobacilli-mediated glycogenolysis, lowering vaginal pH and triggering squamous metaplasia of subcolumnar reserve cells
• Metaplasia advances from the original SCJ inward toward the external os - this process establishes the transformation zone
• CIN typically originates at the advancing SCJ within the transformation zone
• The anterior lip of the cervix is twice as likely to develop CIN as the posterior lip
• Proximally, CIN involves the cervical clefts, which harbor the most severe lesions

---

3. Pathogenesis of Cervical Carcinoma - Step-by-Step Flowchart

SEXUAL TRANSMISSION OF HR-HPV (types 16, 18, 31, 33...)
                    │
                    ▼
        INITIAL HPV INFECTION
   (Infects basal/parabasal cells of transformation zone)
                    │
          ┌─────────┴─────────┐
          ▼                   ▼
   VIRAL CLEARANCE      PERSISTENT INFECTION
   (80-90% of cases)   (10-20% - high risk, older age, smokers)
   → No disease        → CIN progression
                              │
                              ▼
                    EPISOMAL HPV (early infection)
              E6 & E7 expressed at low levels
              → Koilocytic changes → CIN 1 / LSIL
                              │
                              ▼
                  INTEGRATION INTO HOST GENOME
              (disrupts E2 → loss of E6/E7 regulation)
              → Upregulation of E6 and E7 oncoproteins
                → CIN 2/CIN 3 / HSIL
                              │
                    ┌─────────┴─────────┐
                    ▼                   ▼
            E7 ONCOPROTEIN       E6 ONCOPROTEIN
         Binds & inactivates    Binds & degrades
         Rb protein (pRB)       p53 protein
              │                       │
              ▼                       ▼
      Loss of G1 cell           Loss of apoptosis &
      cycle checkpoint          p53-mediated DNA
      → uncontrolled            repair checkpoint
      proliferation             → genomic instability
                    │
                    ▼
         ADDITIONAL MOLECULAR EVENTS:
       • Telomerase activation (hTERT)
       • Chromosomal alterations (LOH)
       • Methylation of TSG promoters
       • RAS mutations, PIK3CA mutations
                    │
                    ▼
        CARCINOMA IN SITU (CIS) / CIN 3
                    │
                    ▼
      INVASIVE CERVICAL CARCINOMA
   (Squamous cell 75-80% | Adenocarcinoma 15-20%)

---

4. Molecular Mechanisms: E6 and E7 Oncoproteins in Detail

E7 Oncoprotein - "The Rb Hijacker"

• Binds preferentially to the underphosphorylated (active) form of pRb
• In normal cells, hypophosphorylated Rb sequesters E2F transcription factors, preventing S-phase entry
• E7-Rb binding releases E2F → cell cycle progression past the G1 checkpoint unchecked
• Result: uncontrolled cellular proliferation
• Paradoxical p16 upregulation occurs as a negative feedback response to E7 activity - this makes p16 immunostaining a useful surrogate marker for HR-HPV infection

E6 Oncoprotein - "The p53 Assassin"

• Binds p53 and recruits ubiquitin ligase E6-AP, targeting p53 for proteasomal degradation
• Abolishes p53-mediated DNA repair checkpoints and apoptosis
• Also activates telomerase (hTERT), conferring replicative immortality
• Epigenetic effects: methylation of tumor suppressor gene promoters (GSPT1, APC, RASSF1)

Viral Integration - The Point of No Return

• In low-grade lesions, HPV exists as episomal (extrachromosomal) circular DNA
• As CIN progresses, HPV DNA integrates into the host genome - disrupting the E2 gene
• Loss of E2 (a transcriptional repressor) leads to upregulated E6/E7 expression
• Integration also causes direct chromosomal instability at insertion sites
• Integration is considered essential for malignant transformation

---

5. Histological Spectrum: CIN Grading

---

6. Risk Factors for Persistence and Progression

---

7. Histological Types of Cervical Cancer

---

8. Screening - From HPV to Diagnosis

• Triage of ASC-US cytology (reflex HR-HPV testing)
• Co-testing with cytology (ages 30-65)
• Primary HPV screening (ages 25-65 per newer guidelines)
• Sensitivity of conventional Pap: 51%; false-negative rate 49%
• HPV testing has sensitivity >90% for CIN 2+

---

9. FIGO Staging 2018 (Current)

2018 FIGO Update: Lymph node status (IIIC1/IIIC2) was added for the first time. Imaging (MRI, CT, PET) is now permissible for staging.

---

10. Vaccination - Primary Prevention

• Vaccines are prophylactic only - they do not clear existing infection
• Target the L1 capsid protein (virus-like particles)
• Most effective when administered before sexual debut
• Recommended ages 9-26 years for both males and females (ACOG/CDC)
• Catch-up vaccination available up to age 45 with shared decision-making
• E6 and E7 oncoproteins are targets for therapeutic vaccines (investigational)

---

11. Summary Table: HPV Molecular Carcinogenesis

---

12. Key Diagnostic Markers (Gynecologic Pathology)

---

• Berek & Novak's Gynecology - Chapter 16: Cervical Intraepithelial Neoplasia, pp. 832-858
• Robbins & Cotran Pathologic Basis of Disease - Viral and Bacterial Oncogenesis, p. 184-190
• Goldman-Cecil Medicine - Viral Carcinogenesis, pp. 2011
• Henry's Clinical Diagnosis and Management by Laboratory Methods - Cervical Cancer, p. 1844
• Histology: A Text and Atlas - Clinical Correlation: HPV and Cervical Cancer, p. 2314